Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Deutsche Bank AG (DB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Deutsche Bank AG — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $352.85 (market cap $9.43B), while Deutsche Bank AG trades at $38.38 (market cap $71.96B). The key difference: Deutsche Bank AG is far larger — about 7.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Deutsche Bank AG pays a 3.04% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | DB | |
|---|---|---|
Market Cap | $9.43B | $71.96B |
Sector | Health | Financials |
52-Week High | $356.25 | $40.33 |
52-Week Low | $241.71 | $28.37 |
Enterprise Value | $9.18B | — |
Dividend Yield | — | 3.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
Deutsche Bank (DB) trades at $38.27, up 0.55% today, with a bullish technical signal from moving averages. The stock shows a discounted valuation with a P/E of 10.07 and P/B of 0.79. Recent Q2 2026 earnings missed expectations at $0.66 per share versus $0.91, but revenue growth remains solid. The company announced a $1.00 dividend and a new share buyback program, supported by strong capital buffers and its recent designation as a clearing bank for China's renminbi (Reuters, 2026-08-10).
The outlook is mixed; strong operational performance and strategic initiatives like AI dealmaking (CNBC, 2026-07-29) offer upside, but earnings volatility and regulatory scrutiny (Reuters, 2026-07-22) pose risks. Analyst consensus is neutral with 57.58% hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →
